中德临床肿瘤学杂志(英文版)2008，Vol.7Issue(4)：196-199,4.
吉西他滨联合顺铂或卡铂方案一线治疗晚期非小细胞肺癌的疗效和毒性比较
Comparison of efficacy and toxicity between gemcitabine plus cisplatin and plus carboplatin in first-line treatment of advanced non-small cell lung cancer
摘要
Abstract
Objective:To compare the efficacy and toxicity between gemdtabine plus cisplatin and plus carboplatin in firstline treatment of advanced non-small call lung cancer (NSCLC).Methods:Gemcitabine 1000 mg/m2 iv,d1,8;cisplatin 75 mg/m2 iv,d1,or 25 mg/m2 iv,d1-3;carboplatin AUC = 5 iv,d1;repeated every 21 days.Results:All 76 cases were available for objective response.Gemcitabine + cisplatin (GCis) group:among 33 cases,CR 1 case,PR 13 cases,MR 3 cases,SD 7 cases,PD 9 cases,response rate,disease control rate,time to progress (TTP),median survival time (MST) and 1-,2-year survival rates were 42.42% (14/33),72.73% (24/33),5 months,14 months and 66.67% (22/33),12.12% (4/33),respectively;Gemcitabine + carboplatin (GCarb) group:among 43 cases,PR 13 cases,MR 11 cases,SD 7 cases,PD 12 cases,the results while comparing with those of GCis group were 30.23% (13/43),72.09% (31/43),4 months,11 months and 48.84% (21/43),2.33% (1/43),respectively.Among them,only MST between the two groups had significant statistic difference (x2 = 2.45,P = 0.017).Mild to modest myelo-suppression as well as nausea and vomiting were observed.Conclusion:Both GCis and GCarb regimens had active and well-tolerated toxicity for advanced NSCLC.Cisplatin-based chemotherapy yields a substantial effective advantage over carboplatin-based regimens.Therefore,carboplatin and cisplatin are not equal-active and that cisplatin-based doublet regimens should remain the standard first-line therapy for patients with advanced NSCLC with good performance status.关键词
advanced non-small cell lung cancer (NSCLC)/chemotherapy/gemcitabine/cisplatin/carboplatinKey words
advanced non-small cell lung cancer (NSCLC)/chemotherapy/gemcitabine/cisplatin/carboplatin分类
医药卫生引用本文复制引用
Meiqi Shi,Bo Shen,Guochun Cao,Yun Zeng,Guohao Xia,Jifeng Feng,Lin Xu..吉西他滨联合顺铂或卡铂方案一线治疗晚期非小细胞肺癌的疗效和毒性比较[J].中德临床肿瘤学杂志(英文版),2008,7(4):196-199,4.基金项目
Supported by a grant from Scientific and Technical Development Project of Jiangsu Province (No.BS2006005). （No.BS2006005）
